09:00 AM EDT, 09/06/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Friday it has dosed the first patient in a phase 2a trial of its drug candidate VTX3232 for early-stage Parkinson's disease.

The company said the study will assess the safety and tolerability of VTX3232, a selective NLRP3 inhibitor, over a 28-day treatment period involving about 10 patients.

Topline data from the trial is expected in 2025, Ventyx said.

Shares of the company were down 1.4% in recent Friday premarket activity.

Price: 2.1400, Change: -0.03, Percent Change: -1.38